Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 clinical trials
Also written QLS31905.
Its developmentBy Qilu Pharmaceutical, step by step6 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Oxaliplatin (1) · Capecitabine (1) · Gemcitabine (1) · Cisplatin (1) · Iparomlimab/Tuvonralimab (1) · Antineoplastic Agents (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905.
Studies
Open first, then newest update. How each study uses Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07716449Written as QLS31905How we know
- A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic CancerRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07079228Written as QLS31905How we know
- Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07151872Written as QLS31905 for InjectionHow we know
- Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT06942767Written as QLS31905 for InjectionHow we know
- Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT06446388Written as QLS31905How we know
- A Study of QLS31905 in Patients With Advanced Solid TumorsStatus unknownPhase 1Qilu Pharmaceutical Co., Ltd.NCT05278832Written as QLS31905How we know